“The science supporting our application is robust, and we are optimistic that we will be able to launch this product to consumers in the coming months.”

In context

“innovation and the switching of legal smoker to better alternative. It is clear from the science that nicotine pouches are a much better choice for those legal edge consumer we would otherwise smoke. We also note the recently published data from the National Youth Tobacco Survey showing that underage usage of the category remained stable or slightly declining at low levels below 2% despite the strong growth of the category. The authorization of [indiscernible] via the FDA's nicotine pouch pilot program remains a priority. Our application remains under active scientific review. And we have a continued dialogue with the FDA as part of this process. The FDA's intent for the pilot program is to increase efficiency and streamline the review process. And while it has taken longer than targeted. The science supporting our application is robust, and we are optimistic that we will be able to launch this product to consumers in the coming months. In addition, we have made a number of ZYN submission to the FDA that are at various stages of the regulatory process, and we are preparing to bring further innovation to market also in the coming months. With regards to IQOS, we are pleased that the FDA has now reauthorized the previous version as a modified risk tobacco product. We continue to engage with the FDA with respect to the authorization of IQOS ILUMA to enable American smokers to access the world's biggest and most successful smoke-free product in achieving full switching away from cigarettes. Overall, we look forward with confidence to the future growth of our U.S. business. Finally, moving to combustible, which once again demonstrated the resilience of our net revenue and gross profit growth model despite significant Q1 speci”